Antibody Shows Promise For Combatting Diverse Strains Of HIV

In preclinical trials, the N6 antibody neutralized 98 percent of 181 HIV strains tested.

Written byJoshua A. Krisch
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA COMMONS, C. GOLDSMITH

An antibody dubbed N6 neutralized 98 percent of HIV strains tested, according to a preclinical study described in Immunity this week (November 15). N6, which was first isolated from an HIV-positive patient, succeeded in recognizing and attacking HIV even as the virus morphed and mutated, suggesting it may be able to combat strains of HIV that have historically proven impervious to antibody-based therapies.

"The discovery and characterization of this antibody with exceptional breadth and potency against HIV provides an important new lead for the development of strategies to prevent and treat HIV infection," Anthony Fauci of the US National Institute of Allergy and Infectious Disease, who was not involved in the study, which his agency funded in part, told ScienceAlert.

HIV often dodges the immune system by swapping out the surface proteins that most antibodies use to track its whereabouts. But N6—much like VRC01, an ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies